http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106075440-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0058
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0052
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-0034
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K49-223
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-66
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K49-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-16
filingDate 2016-06-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2019-04-12-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-106075440-B
titleOfInvention A kind of hepatoma-targeting photo-thermal therapy agent and the preparation method and application thereof
abstract The present invention provides a kind of hepatoma-targeting photo-thermal therapy agents and the preparation method and application thereof, belong to biomedical engineering field.Hepatoma-targeting photo-thermal therapy agent of the invention is prepared by the following method to obtain: (1) preparing biotinylation nanometer microvesicle;(2) the biotinylation resisting GPC 3 antibody of Cy7 fluorescent marker is prepared;(3) biotinylation reproducibility graphene oxide (RGO) is prepared;(4) product made from above three step is coupled as biotin-avidin system to obtain hepatoma-targeting photo-thermal therapy agent.Photo-thermal therapy agent of the invention has ultrasound and fluorescence imaging dual function, technology, which is destroyed, by ultrasound targeted microbubble mediates RGO targeting Delivery, monitor photo-thermal therapy process in real time, which can be used for preparing the drug for the treatment of liver cancer, have excellent clinical value.
priorityDate 2015-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID171548
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6432
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID887
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID94190
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415794038
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419538066
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448098817
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419555088
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID297
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419523852
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/protein/ACCP22629
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559581
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID10340
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID453034310
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558313
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID516892
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411932836
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID679
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6212

Total number of triples: 39.